跳至主要内容
临床试验/ACTRN12622000487718
ACTRN12622000487718尚未招募未知

Metabolomics in Ehancing Responses to ImmunoTherapy - in adult Melanoma patients

Wesley Medical Research0 个研究点目标入组 80 人开始时间: 2022年3月28日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • Patients with resected and unresectable melanoma who are undergoing checkpoint inhibitor therapy.

排除标准

  • Patients with active, untreated brain metastases
  • Patients on > 10mg prednisone at baseline
  • Active autoimmune disease (excludes vitiligo, treated thyroid disease, diabetes)
  • Crohn’s disease or ulcerative colitis
  • The presence of any other neoplasm in the past 5 years – deemed ‘not under control’
  • Inability to give informed consent
  • Hepatitis B or C
  • Prior treatment with immunotherapy – if patient had adjuvant immunotherapy – date of relapse must have been > = 6 months prior to study entry
  • Active mental illness that prohibits study entry
  • Radiotherapy within previous 4 weeks except to brain mets
  • Concurrent use of any other investigational or experimental product or therapeutic

研究者

相似试验